
Fabio Arcidiacono/X
May 5, 2025, 14:31
Fabio Arcidiacono Highlights POPART, PERSIAN, and RADIOSA Trials in Prostate Cancer
Fabio Arcidiacono, Radiation Oncologist at S.Maria Hospital, shared a post on X:
“Localised setting.
POPART trial: predictors toxicity and oncological outcomes salvage SAbR prostate bed
oligo-R hormone-sensitive
2.PERSIAN trial: ADT-APA vs ADT-APA + SAbR
3. substudy RADIOSA trial: liquid biopsy molecular characterization.”
More posts featuring ESTRO25.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
May 5, 2025, 17:25
May 5, 2025, 16:58
May 5, 2025, 15:10
May 5, 2025, 15:06